Global Methotrexate Injection Market - 2024-2031

Global Methotrexate Injection Market - 2024-2031

Global Methotrexate Injection Market reached US$ YY billion in 2022 and is expected to reach US$ YY million by 2031 growing at a CAGR of YY% during the forecast period 2024-2031.

Methotrexate injection works by decreasing inflammation which can reduce pain and prevent long-term injury to the joints and skin. It can also be used to treat some types of cancer by slowing down the growth of cancer cells. Methotrexate is commonly used in the management of rheumatoid arthritis to reduce joint pain, swelling, and damage.

It is also used in the treatment of various autoimmune diseases, such as psoriatic arthritis and juvenile idiopathic arthritis. Methotrexate injections can be administered either intramuscularly or subcutaneously. The choice of route depends on factors such as patient preference, dosage, and the healthcare provider's recommendation.

Market Dynamics

Increasing drug approvals

The increasing drug approvals act as a significant driver for market growth. Methotrexate is a medication that is used to treat various medical conditions, including certain types of cancer, autoimmune diseases, and severe psoriasis.

For instance, in July 2023, Horizon Therapeutics plc received the U.S FDA approval for supplemental Biologics License Application (sBLA) expanding the labeling to include KRYSTEYYA (pegloticase) injection co-administered with methotrexate.

Additionally, in September 2022, Eisai Co., Ltd. and nippon medac Co., Ltd. obtained manufacturing and marketing approval from the Japanese Ministry of Health, Labour and Welfare for Metoject subcutaneous injection used for the treatment of rheumatoid arthritis.

Furthermore, significant growth drivers such as the increasing clinical trials, rising geriatric population, and increasing prevalence of cancers are expected to drive the market in the forecast period.

Side effects of methotrexate injection

The dosage and frequency of Methotrexate can influence the likelihood and intensity of side effects. Common side effects include nausea, vomiting, fatigue and dizziness. Some individuals experienced a reduced appetite while on Methotrexate. Methotrexate can rarely cause gastrointestinal ulcers. The symptoms include abdominal pain, black stools, or vomiting blood. Thus, the above factors can hamper the market growth.

Segment Analysis

The global methotrexate injection market is segmented based on indication, route of administration, distribution channel and region.

The arthritis segment accounted for approximately 36.5% of the market share

The arthritis segment is expected to hold the largest market share over the period forecast. Methotrexate is commonly used in the treatment of various forms of arthritis, particularly rheumatoid arthritis. It is a disease-modifying antirheumatic drug that helps manage symptoms and slow down the progression of the disease.

Methotrexate is a first-line therapy for rheumatoid arthritis, which is an autoimmune condition that primarily affects the joints. It helps reduce inflammation and joint damage. Methotrexate works by inhibiting the activity of dihydrofolate reductase, an enzyme involved in the synthesis of DNA, RNA, and proteins. This inhibition helps reduce inflammation and control the autoimmune response that leads to joint damage in arthritis.

Geographical Analysis

North America is expected to hold a significant position in the global methotrexate injection market share

The global methotrexate injection market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa.

North America has maintained a significant market proportion due to factors such as the rising prevalence of arthritis, drug approvals, and increasing healthcare expenditure, this trend is anticipated to continue throughout the forecast period.

For instance, according to the Centers for Disease Control and Prevention, about 1 in 5 U. S adults (21.2%) or about 53.2 million people had doctor-diagnosed arthritis. It is more common among women (20.9%) compared to men (16.3%). About 44.0% of adults with doctor-diagnosed arthritis had limitations in their usual activities due to their arthritis.

Additionally, according to the Arthritis Society Canada, around 6 million Canadians have arthritis which is 1 in 5 people. Nearly 60% of people with arthritis are women. Around 1 in 4 Canadian women and 1 in 6 Canadian men have arthritis. Hence, due to the above factors, it is expected to drive the region’s growth

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the global methotrexate injection market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular diagnoses, drug launches, and consultations worldwide. With the outbreak of the pandemic, many treatment centers faced labor shortages and were unable to travel to work due to lockdown restrictions. Therefore, owing to the above factors, the methotrexate injection market is expected to be moderately affected over the forecast period.

Market Segmentation

By Indication
• Cancer
• Arthritis
• Psoriasis
• Scleroderma
• Others

By Route of Administration
• Intramuscular
• Subcutaneous

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include Pfizer Inc., Teva Pharmaceutical Industries Ltd, Hikma Pharmaceuticals Plc, Medexus Pharmaceuticals Inc, Aetos Pharma Pvt Ltd, Lupin Limited, Cumberland Pharmaceuticals Inc., Sandoz Group AG, Getwell Oncology Pvt Ltd., Eisai Co. Ltd. among others.

Key Developments
• In October 2023, Shorla Oncology acquired the oncology and autoimmune drug Jylamvo (methotrexate) from Therakind, for commercialization in the US market.
• In December 2021, Assertio Holdings, Inc acquired Otrexup (methotrexate), a drug-device combination single dose once weekly auto-injector from Antares Pharma Inc.

Why Purchase the Report?
• To visualize the global methotrexate injection market segmentation based on indication, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global methotrexate injection market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global methotrexate injection market report would provide approximately 61 tables, 58 figures, and 185 Pages.

Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies